Navigation Links
Synthetic corkscrew peptide kills antibiotic-resistant Gram-negative bacteria
Date:1/24/2013

HOUSTON An engineered peptide provides a new prototype for killing an entire category of resistant bacteria by shredding and dissolving their double-layered membranes, which are thought to protect those microbes from antibiotics.

The synthetic peptide was effective in lab experiments against antibiotic-resistant Gram-negative bacteria, which cause a variety of difficult-to-treat, potentially lethal infections such as pneumonia and sepsis.

The team led by scientists at The University of Texas MD Anderson Cancer Center reported its findings online in advance of print this week at the Proceedings of the National Academy of Science.

"The antibiotic pipeline against multidrug-resistant Gram-negative problem pathogens is a major unmet need in contemporary medicine; as such, our new antimicrobial agent holds immediate promise," said co-senior author Wadih Arap, M.D., professor in MD Anderson's Department of Genitourinary Medical Oncology and the David H. Koch Center.

Arap, Renata Pasqualini, Ph.D., also a co-senior author, professor in genitourinary medical oncology and the Koch center, and colleagues have previously constructed peptide combinations that are in development against cancer and white fat cells.

"The prototype introduced here as an antibiotic candidate has a unique mechanism of action and translational applications readily identified," Pasqualini said.

Gram-negative bacteria that are highly resistant to existing treatments include E. coli, Acinetobacter baumanii, Pseudomonas aeruginosa, and kebsiella pneumonia. These infections are often present in health care settings and most threatening to people with weakened immune systems.

The spiral peptide called KLAKLAKKLAKLAK acts against bacteria by puncturing their lipid bilayer membranes and has only low toxicity toward mammalian cells. These antimicrobial peptides, however, are subject to routine destruction by host enzymes or those generated by the microbe. Combating that effect by increasing the dose heightens both toxicity to other cells and cost.

D- KLAKLAKKLAKLAK destroys microbes, biofilms

Arap, Pasqualini and colleagues engineered a version of KLAKLAKKLAKLAK to use in their combination therapies but had not tested the peptide alone as an antibiotic.

The peptide is made of L-amino acids, the building blocks of life, which makes them vulnerable to destruction. The researchers synthesized a peptidomimetic a version of the peptide using D-amino acids with a reversed peptide sequence, making it more durable.

In a series of lab experiments, the researchers found that D-KLAKLAKKLAKLAK:

  • Kills a variety of strains of E. coli, A. baumanii and P. aeruginosa, including multi-drug resistant strains.

  • Works against Gram-negative bacteria at all phases of growth, including dormant cells that are prone to become resistant.

  • Causes dose-dependent damage to the bacterial membrane resulting in its dissipation and cell death.

  • Specifically disrupts lipids found in Gram-negative bacteria membranes while not affecting membranes in eukaryotic cells cells with the nucleus and other structures enclosed in separate membranes found in mammals and other non-microbial life.

  • Works in combination with the antibiotic piperacillin at lower doses to kill bacteria.

  • Eliminates biofilms, layers of combinations of microbes that adhere to surfaces and provide an ideal setting for bacterial growth.

Next step: Animal model experiments

Arap and Pasqualini note that developing D- KLAKLAKKLAKLAK as a drug will next require experiments in animal models of sepsis and other infections to further gauge the peptide's effectiveness and side effects.

In their cancer and anti-obesity research, the D-peptide is used with targeting agents to hit specific cells. Large preclinical studies in mice, rats and monkeys showed low toxicity at treatment-level concentrations. Their cancer drug in a first-in-human phase I clinical trial revealed side effects that were predictable, dose-dependent and reversible. Even so, toxicity may differ when it's used against bacterial infections.

The peptide was not effective against Gram-positive bacteria, which have thicker cell walls but are generally more vulnerable to antibiotics and the immune system than are Gram-negative bacteria. Gram-positive bacteria include those that cause anthrax, tuberculosis, strep throat and such treatment-resistant infections as Staphylococcus aureus.

Gram-negative bacteria, which have thinner membranes but are generally more resistant to antibiotics or immune system attack, also include those that cause typhoid fever, cholera, gonorrhea, syphilis and lyme disease.


'/>"/>

Contact: Scott Merville
smerville@mdanderson.org
713-792-0661
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Related medicine news :

1. Biosynthetic grape-derived compound prevents progression of Alzheimers disease in mice
2. Stimulant marketed as natural in sports supplement actually of synthetic origin
3. Synthetic stimulants called bath salts act in the brain like cocaine
4. Scientists explore new class of synthetic vaccines
5. Boston University researchers expand synthetic biologys toolkit
6. Synthetic Skin Heals Itself With a Touch, Study Shows
7. Researchers build synthetic membrane channels out of DNA
8. Probiotic Action Issues a Response to an Article on Medical News Today About Synthetic Skin Research
9. Synthetic Pot Sending Thousands of Young People to ER: Report
10. Strange behavior: New study exposes living cells to synthetic protein
11. Combination peptide therapies might offer more effective, less toxic cancer treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , ... April 28, 2016 , ... ... the Year at VitaFoods 2016. , Nominated in the Healthy Ageing category, Cognizin® ... innovation, and safety. The Healthy Ageing division can include everything from antioxidants, lipids, ...
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... ... leader in Aesthetic Surgery Education and Anzu®, developers of the AnzuMedical™ Knowledge ... Nationwide Plastic Surgery Collaborative Residency Network. The platform is scheduled to launch in ...
(Date:4/28/2016)... ... April 28, 2016 , ... April, 28, ... Top Doc in Physical Medicine and Rehabilitation by Philadelphia Magazine. , Philadelphia Magazine’s ... by randomly surveying physicians and medical leadership across the country. These select individuals ...
(Date:4/28/2016)... ... April 28, 2016 , ... Starting today, households across the ... USA Medical Prescription Assistance Program. They are customized to reflect the specific health ... include a ready-to-use, state-themed card and, in the near future, material that highlights ...
(Date:4/28/2016)... Hollywood, CA (PRWEB) , ... April 28, 2016 , ... ... emergency dental care as soon as possible is essential when it comes to dental ... may make the difference between saving and losing a tooth. Toothaches, knocked-out teeth, chipped ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... 27, 2016 ... in Zürich gab Strekin AG den Start ... zur Erhaltung des Resthörvermögens von Patienten, denen ... die umfassende Phase-II-Doppelblindstudie mit Placebo-Kontrollgruppe werden momentan ... wird während der Operation direkt ins Mittelohr ...
(Date:4/27/2016)... April 27, 2016   Zillion Group ... health technology platform, which specializes in live video ... scalable digital products, Zillion enables companies to realize ... consumers to take control of their health. ... conferencing – including one-to-one, group and webcast scheduled ...
(Date:4/27/2016)... Oasmia Pharmaceutical AB (NASDAQ: ... new generation of drugs within human and veterinary ... Paclical/Apealea in the Phase III study that included ... cancer. These preliminary results showed non-inferiority between the ... versus Taxol in combination with carboplatin. In fact, ...
Breaking Medicine Technology: